Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.

MLA

Schou, Morten, et al. “Sacubitril/Valsartan Compared to Ramipril in High‐risk Post‐myocardial Infarction Patients Stratified According to Use of Mineralocorticoid Receptor Antagonists: Insight from the PARADISE MI Trial.” European Journal of Heart Failure, vol. 26, no. 1, Jan. 2024, pp. 130–39. EBSCOhost, https://doi.org/10.1002/ejhf.3079.

APA

Schou, M., Claggett, B., Miao, Z. M., Fernandez, A., Filippatos, G., Granger, C., Jering, K., Maggioni, A. P., McCausland, F., Villota, J. N., Rouleau, J., Mody, F. V., van der Meer, P., Vinereanu, D., McGrath, M., Zhou, Y., Mann, D. L., Solomon, S. D., Steg, P. G., & Braunwald, E. (2024). Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial. European Journal of Heart Failure, 26(1), 130–139. https://doi.org/10.1002/ejhf.3079

Chicago

Schou, Morten, Brian Claggett, Zi Michael Miao, Alberto Fernandez, Gerasimos Filippatos, Christopher Granger, Karola Jering, et al. 2024. “Sacubitril/Valsartan Compared to Ramipril in High‐risk Post‐myocardial Infarction Patients Stratified According to Use of Mineralocorticoid Receptor Antagonists: Insight from the PARADISE MI Trial.” European Journal of Heart Failure 26 (1): 130–39. doi:10.1002/ejhf.3079.